[The CESS 81 cooperative Ewing sarcoma study of the Society for Pediatric Oncology: an interim report].
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001761:Bleomycin / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D012512:Sarcoma, Ewing / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide
Die kooperative Ewing-Sarkom-Studie CESS 81 der GPO: Zwischenbericht.